Jim Cramer openly shares his opinions about various stocks, and on September 3, 2026, during an episode of CNBC's Mad Money, he gave his two cents on Nuvation Bio (NUVB).
A caller asked about the surging biopharma name, and Cramer answered in five plain words: "This is a pure spec."
That is short for pure speculation, which implies a stock that trades on what a drug might do someday, not on the money the company is making right now.
His warning came as the stock climbed on real news, which is exactly what makes Nuvation such a tricky call for investors.
Cramer has hosted Mad Money since 2005 and ran a hedge fund for years before that, so when he flags a stock as too risky for most people, it carries weight.
#cramer #nuvation #pure #shares
A caller asked about the surging biopharma name, and Cramer answered in five plain words: "This is a pure spec."
That is short for pure speculation, which implies a stock that trades on what a drug might do someday, not on the money the company is making right now.
His warning came as the stock climbed on real news, which is exactly what makes Nuvation such a tricky call for investors.
Cramer has hosted Mad Money since 2005 and ran a hedge fund for years before that, so when he flags a stock as too risky for most people, it carries weight.
#cramer #nuvation #pure #shares
5 days ago
